Enhancement of antitumor effect of Tegafur/Uracil (UFT) plus leucovorin by combined treatment with protein-bound polysaccharide, PSK, in mouse models

被引：4

作者：

Katoh, Ryoji ^{[1
]}

Ooshiro, Mitsuru ^{[1
]}

机构：

[1] Toho Univ, Sakura Med Ctr, Dept Surg, Chiba 2748510, Japan

来源：

CELLULAR & MOLECULAR IMMUNOLOGY | 2007年 / 4卷 / 04期

关键词：

UFT; leucovorin; PSK; meth A; Lewis lung carcinoma; colon; 26; antitumor effect;

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 [免疫学];

摘要：

We evaluated the antitumor effect of combined therapy with tegafur/uracil (UFT) plus leucovorin (LV) (UFT/LV) and protein-bound polysaccharide, PSK, in three mouse models of transplantable tumors. UFT/LV showed antitumor effect against Meth A sarcoma, and the antitumor effect was enhanced when PSK given concomitantly. UFT/LV showed antitumor effect to Lewis lung carcinoma and PSK alone also showed antitumor effect at high dose, but a combination of UFT/LV and PSK resulted in no enhanced antitumor effect. Colon 26 carcinoma was weakly responsive to UFT/LV, and no enhancement of antitumor effect was found even PSK was used in combination. In conclusion, while the effect of PSK varies depending on tumor, combined use of UFT/LV and PSK may be expected to augment the antitumor effect.

引用

页码：295 / 299

页数：5

共 36 条

[1]

AKIYAMA J, 1977, CANCER RES, V37, P3042

[2]

Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study [J].

Bajetta, E. ;

Di Bartolomeo, M. ;

Buzzoni, R. ;

Mariani, L. ;

Zilembo, N. ;

Ferrario, E. ;

Lo Vullo, S. ;

Aitini, E. ;

Isa, L. ;

Barone, C. ;

Jacobelli, S. ;

Recaldin, E. ;

Pinotti, G. ;

Iop, A. .

BRITISH JOURNAL OF CANCER, 2007, 96 (03) :439-444

[3]

Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer [J].

Carmichael, J ;

Popiela, T ;

Radstone, D ;

Falk, S ;

Borner, M ;

Oza, A ;

Skovsgaard, T ;

Munier, S ;

Martin, C .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3617-3627

[4]

DONALDSON SS, 1979, CANCER, V43, P2036, DOI 10.1002/1097-0142(197905)43:5+<2036::AID-CNCR2820430712>3.0.CO

[5]

2-7

[6]

Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer [J].

Douillard, JY ;

Hoff, PM ;

Skillings, JR ;

Eisenberg, P ;

Davidson, N ;

Harper, P ;

Vincent, MD ;

Lembersky, BC ;

Thompson, S ;

Maniero, A ;

Benner, SE .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3605-3616

[7]

FUJII S, 1978, GANN, V69, P763

[8]

FUJII S, 1979, JPN J CANC CHEMOTHER, V6, P373

[9]

A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer [J].

Goldberg, RM ;

Sargent, DJ ;

Morton, RF ;

Fuchs, CS ;

Ramanathan, RK ;

Williamson, SK ;

Findlay, BP ;

Pitot, HC ;

Alberts, SR .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :23-30

[10]

GOLDBERG RM, 2007, J CLIN ONCOL S18S, V25, pS166

← 1 2 3 4 →